AOD-9604

A synthetic 16-residue cyclic peptide corresponding to the C-terminal domain of human growth hormone, characterized by NMR conformational analysis and bioanalytical structure studies.

Molecular Profile

Type
Synthetic peptide (cyclic, 16 residues)
Molecular formula
C78H123N23O23S2
Molecular weight
~1,815 g/mol
CAS number
221231-10-3
Amino acids
16
Sequence
YLRIVQCRSVEGSCGF
Modification
N-terminal tyrosine extension of the hGH 177–191 sequence; intramolecular Cys7–Cys14 disulfide bond forming a cyclic loop.

Mechanism & Target Class

A disulfide-cyclized 16-residue peptide corresponding to the C-terminal domain of human growth hormone (residues 177–191 plus an N-terminal tyrosine). The N-terminal tyrosine extension and the intramolecular Cys7–Cys14 disulfide bond constrain the backbone into a cyclic loop; NMR conformational analysis of the solution structure identifies type I β-turns in this region. The cyclic loop is distinct from the N-terminal region of the full-length protein, and the tyrosine modification was introduced to improve stability relative to the unmodified C-terminal fragment.

Storage & Handling

Lyophilized
-20 °C or colder, protected from light and moisture; stable for extended periods when kept frozen and sealed.
Handling
Avoid repeated freeze–thaw cycles; protect from light and moisture; the disulfide is oxidation-sensitive — avoid reducing agents. The N-terminal tyrosine modification was introduced to improve stability relative to the unmodified C-terminal fragment.

Primary Database

PubChem CID 71300630 ↗

References (21)

  1. Reviews

    1

    Mendias CL, Awan TM. (2026). Sports Medicine

    DOI: 10.1007/s40279-026-02437-0

  2. 2

    Kopchick JJ, et al. (2020). Nat Rev Endocrinol

    DOI: 10.1038/s41574-019-0280-9PubMed 31863149

  3. 3

    Moré MI, Kenley D. (2014). Journal of Endocrinology and Metabolism

    DOI: 10.14740/jem213w

  4. 4

    Stier H, Vos E, Kenley D. (2013). Journal of Endocrinology and Metabolism

    DOI: 10.4021/jem157w

  5. 5

    Liao HJ, et al. (2024). Cartilage

    DOI: 10.1177/19476035241276406PubMed 39291443

  6. 6

    Vijayakumar A, et al. (2010). Growth Horm IGF Res

    DOI: 10.1016/j.ghir.2009.09.002PubMed 19800274

  7. Primary research

    7

    Cox HD, et al. (2015). Drug Test Anal

    DOI: 10.1002/dta.1715PubMed 25208511

  8. 8

    Kwon DR, Park GY. (2015). Ann Clin Lab Sci

    PubMed 26275694

  9. 9

    Vanhee C, et al. (2014). Drug Test Anal

    DOI: 10.1002/dta.1687PubMed 24976118

  10. 10

    Orlovius AK, et al. (2013). Drug Test Anal

    DOI: 10.1002/dta.1557PubMed 24124033

  11. 11

    Heffernan M, et al. (2001). Endocrinology

    DOI: 10.1210/endo.142.12.8526PubMed 11713213

  12. 12

    Heffernan MA, et al. (2001). Int J Obes

    DOI: 10.1038/sj.ijo.0801740PubMed 11673763

  13. 13

    Heffernan MA, et al. (2000). Am J Physiol Endocrinol Metab

    DOI: 10.1152/ajpendo.2000.279.3.E501PubMed 10950816

  14. 14

    Ng FM, et al. (2000). Horm Res

    DOI: 10.1159/000053183PubMed 11146367

  15. 15

    Ng FM, et al. (2000). J Mol Endocrinol

    DOI: 10.1677/jme.0.0250287PubMed 11116208

  16. 16

    Ogru E, et al. (2000). J Pept Res

    DOI: 10.1034/j.1399-3011.2000.00771.xPubMed 11153573

  17. 17

    Wijaya E, Ng FM. (1993). Biochem Mol Biol Int

    PubMed 8118430

  18. 18

    Wu Z, Ng FM. (1993). Biochem Mol Biol Int

    PubMed 8358331

  19. 19

    Ng FM, Bornstein J. (1978). American Journal of Physiology

    DOI: 10.1152/ajpendo.1978.234.5.E521PubMed 645904

  20. 20

    Zhao L, Jiang H. (2023). Front Endocrinol

    DOI: 10.3389/fendo.2022.1028191PubMed 36686475

  21. 21

    Høyer KL, et al. (2020). Physiol Rep

    DOI: 10.14814/phy2.14373PubMed 32073221